The RALES Legacy and Finerenone Use on CKD Patients.
作者信息
Moura-Neto José A, Ronco Claudio
机构信息
Department of Internal Medicine, Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil.
Department of Nephrology Dialysis & Transplantation, International Renal Research Institute, San Bortolo Hospital, Department of Medicine - DIMED, University of Padova, Vicenza, Italy.
出版信息
Clin J Am Soc Nephrol. 2021 Sep;16(9):1432-1434. doi: 10.2215/CJN.02150221. Epub 2021 Aug 6.
Abstract
摘要
相似文献
1
The RALES Legacy and Finerenone Use on CKD Patients.
Clin J Am Soc Nephrol. 2021 Sep;16(9):1432-1434. doi: 10.2215/CJN.02150221. Epub 2021 Aug 6.
2
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30.
3
Finerenone: First Approval.
Drugs. 2021 Oct;81(15):1787-1794. doi: 10.1007/s40265-021-01599-7.
4
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Eur J Heart Fail. 2022 Jun;24(6):996-1005. doi: 10.1002/ejhf.2469. Epub 2022 May 19.
5
[Finerenone: a new step on the way to nephroprotection].
Rev Med Suisse. 2022 Aug 24;18(792):1534-1538. doi: 10.53738/REVMED.2022.18.792.1534.
6
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25.
7
New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone.
Cardiovasc Res. 2022 Mar 25;118(5):e36-e37. doi: 10.1093/cvr/cvac024.
8
Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Expert Opin Pharmacother. 2021 Jul;22(10):1253-1256. doi: 10.1080/14656566.2021.1904892. Epub 2021 Mar 25.
9
[Finerenone in patients with chronic kidney disease and type 2 diabetes mellitus].
Internist (Berl). 2021 May;62(5):577-580. doi: 10.1007/s00108-021-01028-7. Epub 2021 Apr 20.
10
Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease.
Kidney Blood Press Res. 2022;47(4):219-228. doi: 10.1159/000521908. Epub 2022 Jan 14.
引用本文的文献
1
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events.
Clin Diabetes. 2024 Sep 20;43(1):43-52. doi: 10.2337/cd24-0036. eCollection 2025 Winter.
2
The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
Nephrol Dial Transplant. 2023 Oct 31;38(11):2503-2516. doi: 10.1093/ndt/gfad101.
3
Analysis of urine Raman spectra differences from patients with diabetes mellitus and renal pathologies.
PeerJ. 2023 Feb 27;11:e14879. doi: 10.7717/peerj.14879. eCollection 2023.
4
Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 15;6(6):536-551. doi: 10.1016/j.mayocpiqo.2022.09.002. eCollection 2022 Dec.
5
Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Front Pharmacol. 2022 Feb 7;13:819327. doi: 10.3389/fphar.2022.819327. eCollection 2022.
6
Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.
J Hum Hypertens. 2022 Aug;36(8):695-704. doi: 10.1038/s41371-021-00641-1. Epub 2022 Jan 4.
7
Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.
Clin J Am Soc Nephrol. 2022 Mar;17(3):455-457. doi: 10.2215/CJN.13541021. Epub 2021 Dec 1.
Zotero 插件